<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926419</url>
  </required_header>
  <id_info>
    <org_study_id>CAPPesq 0911/08</org_study_id>
    <nct_id>NCT00926419</nct_id>
  </id_info>
  <brief_title>Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery</brief_title>
  <acronym>InjHepAVar</acronym>
  <official_title>Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess immunogenicity and safety of nd influence of the delivery system
      (needle-free injector or syringe with needle) of fractional doses (dose sparing) of two
      vaccines (Varicella and Hepatitis A vaccines) in children aged 13 to 30 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity, safety and influence of the
      delivery system (needle-free injector or syringe with needle) of fractional doses (dose
      sparing) (23,3 and 43,3 PFU - plaque-forming units - of live attenuated OKA strain of
      Varicella-zoster virus and 100 radioimmunoassay units HAV) of chickenpox and Hepatitis A (
      vaccines, intradermally administered, compared with full dose of 103,3 PFU, subcutaneously
      administered, in 600 primo (first) vaccinated children aged 13 to 30 months selected at
      random at day care centers in SÃ£o Paulo. Vaccines will be tested sequentially (Varicella on
      day 0 and Hepatitis A on day 45). Only 400 children will be randomized again for Hepatitis A
      vaccine testing, the remaining 200 children will receive the regular dose of Hepatitis A
      vaccine without further assessment. Doses will be administered using two systems: Disposable
      Needle-free Syringe Jet Injector (DSJI), compared with the conventional procedure using
      syringes and needles. Serial blood samples will be blindly analyzed to detect antibody
      seroconversion. Local and systemic adverse events will be assessed according to definition
      established by Brighton Collaboration Group, 24 and 72 hours, 7 days, 14 days, 21 days and 45
      days after each vaccination, through clinical evaluation and telephone calls.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: General seroconversion rate 45 days following immunization. Safety: General rate of local and systemic adverse events after immunization according to definition established by Brighton Collaboration Group</measure>
    <time_frame>45 days after immunization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree and duration of local and systemic adverse events after immunization according to the Brighton Collaboration Group recommendations.</measure>
    <time_frame>45 days after immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rates and number of local and systemic adverse events after immunization according to delivery system (needle-free injector or syringe with needle) for each dose tested</measure>
    <time_frame>45 days after immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual volume administered intradermally according to the delivery system (needle-free injector or syringe with needle) for each fractional dose tested</measure>
    <time_frame>At immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' parents or legal guardians acceptability according to the delivery system (needle-free injector or syringe with needle) for each dose tested</measure>
    <time_frame>45 days after immunization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of vaccine jet evaluated through ultrasound for the needle-free injector group</measure>
    <time_frame>5 minutes after immunization</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Varicella</condition>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Varicella (1/5 dose) - ID - Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella (1/5 dose) - ID - Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella (2/5 dose) - ID - Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella (2/5 dose) - ID - Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella (full dose) - SC - Injector</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varicella (full dose) - SC - Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A (1/5 dose) ID - Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A (1/5 dose) ID - Syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A (full dose) IM - Injector</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis A (full dose) IM - Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella Vaccine</intervention_name>
    <description>Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)</description>
    <arm_group_label>Varicella (1/5 dose) - ID - Injector</arm_group_label>
    <arm_group_label>Varicella (1/5 dose) - ID - Syringe</arm_group_label>
    <arm_group_label>Varicella (2/5 dose) - ID - Injector</arm_group_label>
    <arm_group_label>Varicella (2/5 dose) - ID - Syringe</arm_group_label>
    <arm_group_label>Varicella (full dose) - SC - Injector</arm_group_label>
    <arm_group_label>Varicella (full dose) - SC - Syringe</arm_group_label>
    <other_name>PharmaJet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A Vaccine</intervention_name>
    <description>Hepatitis A virus vaccine, inactivated, Single dose</description>
    <arm_group_label>Hepatitis A (1/5 dose) ID - Injector</arm_group_label>
    <arm_group_label>Hepatitis A (1/5 dose) ID - Syringe</arm_group_label>
    <arm_group_label>Hepatitis A (full dose) IM - Injector</arm_group_label>
    <arm_group_label>Hepatitis A (full dose) IM - Syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of both genders older than 13 months and younger than 30 months of age.

          -  Available for follow-up for at least 45 days at public day care centers funded by SÃ£o
             Paulo City local government.

          -  Written informed consent signed by parents or legal guardians after reading and
             explanation

        Exclusion Criteria:

          -  Suspect/verified diagnosis of congenital or acquired immunodeficiency syndrome (AIDS)

          -  Suspect/verified diagnosis of malign neoplasia

          -  Children on treatment with high-dose systemic corticosteroids (equivalent to
             prednisone 2 mg/kg/day, for two or more weeks), or immunosuppressive therapy.

          -  Received a vaccine with live attenuated strain of virus within less than 30 days

          -  Suspect/verified diagnosis of chickenpox or has already been immunized against
             chickenpox (varicella).

          -  Suspect/verified diagnosis of hypersensibility to any ingredient of the vaccine.

          -  One of the parents or legal guardians of the minor does not agree with the study.

          -  Any other circumstances that may potentially damage the minor or prevent procedures
             from being carried out according to evaluation of the research team.

          -  Child shows signs or symptoms of an active intercurrent disease (e.g. fever, rash,
             etc.) that may interfere with the evaluation of adverse events after immunization at
             the research team's discretion. In this case, the participant may be reevaluated
             within the following three months in order to verify eligibility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Months</minimum_age>
    <maximum_age>30 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glacus S Brito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Disciplina de Immunologia ClÃ­nica e Alergia do HC- FMUSP</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glacus S Brito, MD</last_name>
      <phone>+55(11)30696225</phone>
      <email>glacus@usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>June 22, 2009</last_update_submitted>
  <last_update_submitted_qc>June 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Glacus de Souza Brito</name_title>
    <organization>Hospital das ClÃ­nicas da Faculdade de Medicina da Universidade de SÃ£o Paulo</organization>
  </responsible_party>
  <keyword>Varicella</keyword>
  <keyword>Hepatitis A</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Injector</keyword>
  <keyword>Fractional dose</keyword>
  <keyword>Intradermal</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

